uPA/uPAR signaling in rheumatoid arthritis: Shedding light on its mechanism of action

Dinesh, Palani; Rasool, Mahaboobkhan

doi:10.1016/j.phrs.2018.05.016

Cited by 46 publications

(37 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Urokinase plasminogen activator receptor (uPAR) is a membrane‐bound receptor that mainly expresses on immunologically active cell membrane and participates in various physiological and pathological processes, such as inflammation and immune responses . Circulating suPAR originates from shedding of the uPAR and expressed on a variety of cells, such as neutrophils, lymphocytes, macrophages, and endotheliocytes .…”

Section: Introductionmentioning

confidence: 99%

“…Urokinase plasminogen activator receptor (uPAR) is a membrane-bound receptor that mainly expresses on immunologically active cell membrane and participates in various physiological and pathological processes, such as inflammation and immune responses. 5,6 Circulating suPAR originates from shedding of the uPAR and expressed on a variety of cells, such as neutrophils, lymphocytes, macrophages, and endotheliocytes. 7 Emerging evidence indicates that suPAR is involved in various biological functions, including cell adhesion, migration, and chemotaxis, and its increased level is associated with poor clinical outcomes in various inflammatory diseases, such as sepsis, bacteremia, and SIRS.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Soluble urokinase plasminogen activator receptor associates with higher risk, advanced disease severity as well as inflammation, and might serve as a prognostic biomarker of severe acute pancreatitis

Zhang

Chen

et al. 2019

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background This study aimed to explore the potential of soluble urokinase plasminogen activator receptor (suPAR) as a biomarker for severe acute pancreatitis (SAP) risk prediction and disease management in SAP patients. Methods Totally 225 acute pancreatitis (AP) patients (including 75 SAP, 75 moderate‐severe acute pancreatitis [MSAP], and 75 mild acute pancreatitis [MAP] patients) were recruited based on the Atlanta classification, and their serum samples were obtained within 24 hours after admission. Meanwhile, 75 health controls (HCs) were recruited with their serum samples collected at the enrollment. The serum suPAR was then detected using enzyme‐linked immunosorbent assay. Results The suPAR level was increased in SAP patients compared with MSAP patients (P = .023), MAP patients (P < .001), and HCs (P < .001). Receiver operating characteristic (ROC) curve presented that suPAR could not only differentiate SAP patients from HCs (AUC: 0.920, 95%CI: 0.875‐0.965) but also differentiate SAP patients from MSAP (AUC: 0.684, 95%CI: 0.600‐0.769) and MAP patients (AUC: 0.855, 95%CI: 0.797‐0.912). In SAP patients, suPAR was positively correlated with Ranson score (P < .001), acute physiology and chronic healthcare evaluation II score (P = .001), sequential organ failure assessment score (P < .001), and C‐reaction protein (P = .002). Further ROC curve exhibited that suPAR (AUC: 0.806, 95%CI: 0.663‐0.949) was of good value in predicting increased inhospital mortality of SAP patients. Conclusion Soluble urokinase plasminogen activator receptor is of good predictive value for SAP risk and may serve as a potential biomarker for disease severity, inflammation, and inhospital mortality in SAP patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Soluble urokinase plasminogen activator receptor associates with higher risk, advanced disease severity as well as inflammation, and might serve as a prognostic biomarker of severe acute pancreatitis

Zhang

Chen

et al. 2019

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“…Survivin, also called baculoviral inhibitor of apoptosis repeat-containing (BIRC5), API4, EPR-1, or baculoviral IAP repeat-containing 5, is a protein that, in humans, is encoded by the BIRC5 gene. [44][45][46] Survivin is currently found to be the most potent cell survival antiapoptotic regulator. 47,48 Antitumor drugs used in molecular targeted therapy can damage and kill tumor cells, or damage and cause death due to injury factors.…”

Section: Discussionmentioning

confidence: 99%

<p>miR-596 suppresses the expression of Survivin and enhances the sensitivity of osteosarcoma cells to the molecular targeting agent anlotinib</p>

Wang

Yang

et al. 2019

OTT

View full text Add to dashboard Cite

Background: Osteosarcoma (OSA), the most common primary bone malignancy, is characterized by a wide spectrum of complicated pathologies and frequent distal metastasis and causes death in adolescents and young adults worldwide. Antitumor drug treatment strategies include various cytotoxic chemotherapy drugs, while molecular targeted therapy for OSA is currently less used. The present work revealed the role played by the miR-596/Survivin axis in affecting the sensitivity of OSA cells to anlotinib, a novel molecular targeting agent. Methods: By virtual screening, we found that miR-596 might target Survivin by using an online tool (miRDB). RNA levels of miR-596 and Survivin in clinical specimens were examined with qPCR. The effect of miR-596 on anlotinib's antitumor effect was examined with MTT experiments, the subcutaneous tumor model, or the intramuscular tumor model. Results: Overexpression of miR-596 via lentiviral particles repressed the protein level of Survivin in U2OS cells. Transfection of miR-596 enhanced the antitumor effect of anlotinib on U2OS cells or five cell lines derived from OSA patients. Conclusion: miR-596 targets Survivin and enhances the antitumor effect of anlotinib on OSA cells.

show abstract

“…Over the last 20 years, evidence has accumulated (summarized in reviews [2][3][4]) showing that many disorders are accompanied by increased levels of suPAR. Among these diseases are chronic autoimmune disorders, solid tumour malignancies and chronic heart failure.…”

Section: Positionmentioning

confidence: 99%

“…Among these diseases are chronic autoimmune disorders, solid tumour malignancies and chronic heart failure. More precisely, the activation of uPAR takes place at the level of the cell membrane of chondrocytes and osteocytes in patients with rheumatoid arthritis and mediated bone resorption [2]. suPAR is increased in patients with colorectal cancer, ovarian cancer, breast cancer and prostate cancer, and it is an indicator of unfavourable prognosis [3].…”

Section: Positionmentioning

confidence: 99%

Prognostic Role of Soluble Urokinase Plasminogen Activator Receptor at the Emergency Department: A Position Paper by the Hellenic Sepsis Study Group

et al. 2020

View full text Add to dashboard Cite

show abstract

uPA/uPAR signaling in rheumatoid arthritis: Shedding light on its mechanism of action

Cited by 46 publications

References 101 publications

Soluble urokinase plasminogen activator receptor associates with higher risk, advanced disease severity as well as inflammation, and might serve as a prognostic biomarker of severe acute pancreatitis

Soluble urokinase plasminogen activator receptor associates with higher risk, advanced disease severity as well as inflammation, and might serve as a prognostic biomarker of severe acute pancreatitis

<p>miR-596 suppresses the expression of Survivin and enhances the sensitivity of osteosarcoma cells to the molecular targeting agent anlotinib</p>

Prognostic Role of Soluble Urokinase Plasminogen Activator Receptor at the Emergency Department: A Position Paper by the Hellenic Sepsis Study Group

Contact Info

Product

Resources

About